New statement released by anticoagulation forum

New statement released by anticoagulation forum
The Anticoagulation Forum has endorsed a new consensus statement aimed at optimizing the delivery of anticoagulation therapy to inpatients; the statement has been published in the May issue of the Annals of Pharmacotherapy.

(HealthDay)—The Anticoagulation Forum has endorsed a new consensus statement aimed at optimizing the delivery of anticoagulation therapy to inpatients; the statement has been published in the May issue of the Annals of Pharmacotherapy.

Edith A. Nutescu, Pharm.D., from the University of Illinois at Chicago, and colleagues from the Anticoagulation Forum reviewed the medical literature to identify published articles relating to the standards of practice, national guidelines, patient safety initiatives, and regulatory requirements pertaining to anticoagulant use in the inpatient setting.

The recommendations endorsed by the Anticoagulation Forum and included in the statement are aimed at informing the development of coordinated care systems containing elements with demonstrated benefit in improvement of outcomes. The paper addresses the areas of process, accountability, integration, standards of practice, provider education and competency, patient education, care transitions, and outcomes.

"This document provides consensus guidelines for anticoagulant therapy in the inpatient setting and serves as a companion document to prior guidelines relevant for outpatients," the authors write.

More information: Abstract
Full Text

add to favorites email to friend print save as pdf

Related Stories

New blood-thinner measures may cut medication errors

May 22, 2013

Blood thinners are the preferred treatment option to prevent heart attacks, blood clots and stroke, but they are not without risk, and not just because of their side effects. These high-risk drugs, known as anticoagulants, ...

Recommended for you

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

Tough-to-abuse formulation of oxycodone approved

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe pain when other ...

EU regulator: Morning-after pill OK for all women

Jul 24, 2014

(AP)—A commonly used morning-after pill is suitable for use by heavier women, the European Medicines Agency said Thursday after a review of the evidence sparked by the French manufacturer's declaration that the drugs didn't ...

Physicians warned about counterfeit medical devices

Jul 24, 2014

(HealthDay)—Physicians should be aware of the prevalence and serious consequences associated with use of counterfeit medical devices, according to a letter to the editor published online July 20 in Lasers in ...

User comments